Parvovirus B19 NAT Screening and Infectivity Mei-ying W Yu CBER/FDA SoGAT XVI Paul Ehrlich Institut July 03, 2003.

Slides:



Advertisements
Similar presentations
National Institute for Biological Standards and Control Assuring the quality of biological medicines Proposal for a Hepatitis A genotype panel Rob Anderson.
Advertisements

Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Blood Donor Written Statement of Understanding
Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
1 Babesia BPAC: FDA Perspective Sanjai Kumar, PhD Division of Emerging and Transfusion- Transmitted Diseases Office of Blood Research and Review CBER,
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
Testing Source Plasma for Hepatitis B Virus by Nucleic Acid Testing Blood Products Advisory Committee Meeting Blood Products Advisory Committee Meeting.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
Limitations of HBsAg testing in the screening of blood donors Wolfram H. Gerlich Institute of Medical Virology University Giessen, Germany SoGAT XVI Langen.
Deferral of MSM by Andrew I. Dayton, M.D., Ph. D. The HIV epidemic in the U.S.A. is generally recognized to have started just after Currently MSM.
Update: Lowering Measles Antibody Lot Release Specification in IGIV/IGSC Blood Products Advisory Committee May 1, 2008 Dorothy Scott, M.D. Division of.
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
BioLife Plasma Services Experience with HBV NAT Testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
Transmissibility of B19 by transfusion: evaluation of donor viremia prior to performing a linked donor-recipient study M Busch, representing REDS-II Parvo.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.
E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.
1 Donor’s Written Statement of Understanding Beth H. Shaz, MD Chief Medical Officer New York Blood Center Clinical Associate Professor Emory University.
Current Considerations on Plasma for Further Manufacturing Obtained from Whole Blood Donors Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs,
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.
Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.
1 B19 Testing of Plasma for Fractionation: Current Thinking Mei-ying W Yu, PhD Division of Hematology CBER/FDA SoGAT XVII May 26-27, 2004.
Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.
Anti-B19 screening for safe cellular blood products for at–risk patients SoGAT XVIII, USA, May 24-25th, 2005 Harry Bos on behalf of Project Group Parvo.
CBER 1 Disease Associated Antibody Donor Program Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.
Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Issues Related to Implementation of Blood Donor Screening for Infection with Trypanosoma cruzi Presentation to BPAC April 26, 2007 Robert Duncan, PhD.
Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.
SoGAT 2005 Donor screening for parvovirus B19 antibodies: Reducing or eliminating the risk of transmission SoGAT 2005 Gordon Elliott Biotrin 93 The Rise.
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.
Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
Risk Assessment: Questions to the Committee 1.What estimate(s) should be used to reflect the prevalence of vCJD in the U.K.? Proposal: We propose using.
Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.
E B—Anti-HBc Chart 1 10/2004 Anti-HBc Testing and Donor Reentry Results of a Pilot Study Susan L. Stramer, Ph.D. American Red Cross Blood Products.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.
Slide 1 "CJD Lookback Study" (Research Study to Assess the Risk of Blood Borne Transmission of CJD) American Red Cross Blood Services TSEAC October 14,
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVI, Langen 3 rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and.
CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.
FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.
December 12, 2002 Blood Products Advisory Committee Draft Presentation 1 Parvovirus B19 Public Health Impact of Donor Notification and Counseling Edward.
FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors Michael P. Busch representing Blood Systems Research Institute Blood.
Sean Doyle National University of Ireland, Maynooth, Ireland. Parvovirus B19 Infection in Seronegative and Seropositive Individuals – Implications for.
Presented by Karen Dosanjh Quality Director Blood Systems
2015 Haemovigilance Report Tables and Figures
This is an archived document.
Laboratory Assays for Epstein-Barr Virus-Related Disease
Update on CBER HIV-1 Subtype panel
Viral Safety of Blood Products in Taiwan
Laboratory Assays for Epstein-Barr Virus-Related Disease
CMV Working Group Update to NAC April 2016.
NUCLEIC ACID AMPLIFICATION TESTING DETECTS HIV TRANSMISSION RISK IN SEROLOGICALLY- TESTED BLOOD DONOR UNITS. |Presented by Miss Shemau Muniru| Authors:
SoGAT meeting XXI May (2009), Brussels, Belgium
Presentation transcript:

Parvovirus B19 NAT Screening and Infectivity Mei-ying W Yu CBER/FDA SoGAT XVI Paul Ehrlich Institut July 03, 2003

B19 NAT/BPAC Sep 1999 Pending a policy on screening Whole Blood donations, FDA need not require studies to validate the clinical effectiveness of NAT for B19 DNA under IND for plasma for further manufacturing –B19 NAT as an in-process test, unlike HIV/HCV/HBV NAT –Quarantine and destroy in-date units when possible (However, BPAC did not recommend resolving to the single donation/donor. For S/D Treated Pooled Plasma, the reactive 20-unit subpools were discarded (when tests completed, labile components had expired)

B19 NAT/Dec 2001 FDA NAT WKSP Source Plasma Fractionators –High-titer B19 minipool NAT screening (10 5 to 10 7 geq/mL of original donation) as an in-process test –Reactive minipools are resolved to single donations –Results are used to reject reactive donations Whole Blood Establishments –Would like to implement high-titer B19 NAT screening similar to that used by SP fractionators Phase I: not resolve to single donations; labile components would have expired. Phase II: resolve to single donations by a free- standing test kit

B19 NAT/BPAC Mar 2002 (I) FDA’s Current Thinking on B19 NAT 1. Plasma: When identified, high-titer B19 reactive units should not be used for further manufacturing into injectable products. This is to ensure that the FDA’s proposed limit, <10 4 IU of B19 DNA/mL, for manufacturing pools destined for making plasma derivatives can be met. 2. Whole Blood: When feasible, B19 reactive minipools should be resolved to identify the individual reactive donors prior to release of components for transfusion; units from reactive donors should not be used for transfusion.

B19 NAT/BPAC Mar 2002 (II) 3. Whole Blood: When testing is done subsequent to product release, in-date components from potentially reactive donors should be retrieved and discarded so that they are not used for transfusion or further manufacturing into injectable products. 4. Even when performed as an “in-process” test (i.e., not performed pre-release as part of a determination of donor eligibility or product labeling), testing and identification of the individual reactive donor constitutes medical diagnostic testing. Therefore, such testing would require the use of an FDA-approved investigational mechanism (e.g., IDE).

B19 NAT/BPAC Dec 2002 BPAC Recommendations 1. Reduce the risks to transfusion recipients by withholding high-titer positive units (  10 6 geq/mL) of Whole Blood (WB) and its components from use –However, the overall value of screening WB donors has not been established 2.Temporarily defer plateletpheresis donors, but not WB or Source Plasma donors 3.Potential medical benefits to close contacts of B19 infected donors warrant notification of high-titer donors –Only if donor notification can be completed within several weeks of donations

B19 Infectivity Studies 1. In-vitro model (UT-7/EPO) –Infectious Anti-B19 (-) plasma with  10 4 geq/mL of B19 DNA Anti-B19 IgM (+) plasma with 10 8 geq/mL –Not infectious Anti-B19 IgG (+) plasma with 10 6 geq/mL 2. Investigated a case report received by the FDA for the possible transmission by a high- purity factor VIII concentrate –Causal relationship between the product and the recipient –Infection occurred when the seronegative recipient received 30,000 geq of B19 DNA